secwatch.observer — SEC 8-K summary
======================================

Issuer:     Z Squared Inc. (ZSQR)
CIK:        0001759186
Form:       8-K
Filed at:   2023-08-22T23:59:59+00:00
Accession:  0001683168-23-005994
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coeptis completes exclusive license of Deverra allogeneic NK cell platform and two Phase 1 assets
--------------------------------------------------------------------------------

- Paid ~$570K cash and issued 4M shares to Deverra for exclusive rights to allogeneic stem cell expansion platform.
- Acquired two IND applications and Phase 1 trials (NCT04901416, NCT04900454) for NK cell therapy DVX201.
- Platform generates off-the-shelf NK and myeloid cells; aligns with Coeptis' SNAP-CAR and GEAR technologies.
- Transaction moves Coeptis from pre-clinical to a clinical-stage company with two ongoing Phase 1 studies.
- Pipeline includes unmodified NK cells for AML/MDS and viral infections plus engineered NK/MAC candidates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/0001683168-23-005994-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/coeptis_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-005994

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer